Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system

Journal of Immunology

Volumn 173, Issue 9, 2004, Pages 5776-5785

  Johnson, Zoë ^a,e   Kosco Vilbois, Marie H ^a,f   Herren, Suzanne ^a,f   Cirillo, Rocco ^b   Muzio, Valeria ^b   Zaratin, Paola ^b   Carbonatto, Michela ^b   Mack, Matthias ^c   Smailbegovic, Amir ^d,g   Rose, Mark ^d   Lever, Rebecca ^d,g   Page, Clive ^d   Wells, Timothy N C ^a   Proudfoot, Amanda E I ^a  

^a SERONO PHARMACEUTICAL RES INSTITUTE   (Switzerland)

^b Merck Serono SpA   (Italy)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e UCB PHARMA   (Belgium)

^f NOVIMMUNE SA   (Switzerland)

^g UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCL5; CHEMOKINE RECEPTOR CCR5; DIMER; GLYCOSAMINOGLYCAN; HAPTEN; HEPARIN; LIGAND; OLIGOMER; RANTES; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNITY; BINDING SITE; CENTRAL NERVOUS SYSTEM; CHEMOTAXIS; CHRONIC DISEASE; CONTROLLED STUDY; GENE MUTATION; GENE OVEREXPRESSION; IMMUNOCOMPETENT CELL; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY CELL; LIGAND BINDING; LUNG; MOUSE; NONHUMAN; OLIGOMERIZATION; PERITONEAL CAVITY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; RECEPTOR BINDING; RECEPTOR DOWN REGULATION;

EID: 6344269426     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.9.5776     Document Type: Article

References (48)

1. Rollins, B. J. 1997. Chemokines. Blood 90:909.
2. Campbell, D. J., C. H. Kim, and E. C. Butcher. 2003. Chemokines in the systemic organization of immunity. Immunol. Rev. 195:58.
3. Gerard, C., and B. J. Rollins. 2001. Chemokines and disease. Nat. Immunol. 2:108.
4. Proudfoot, A. E., C. A. Power, C. Rommel, and T. N. Wells. 2003. Strategies for chemokine antagonists as therapeutics. Semin. Immunol. 15:57.
5. Rot, A. 1993. Neutrophil attractant/activation protein-1 (interleukin-8) induces in vitro neutrophil migration by haptotactic mechanism. Eur. J. Immunol. 23:303.
6. Middleton, J., S. Neil, J. Wintle, L. I. Clark, H. Moore, C. Lam, M. Auer, E. Hub, and A. Rot. 1997. Transcytosis and surface presentation of IL-8 by venular endothelial cells. Cell 91:385.
7. McFadden, G., and D. Kelvin. 1997. New strategies for chemokine inhibition and modulation: you take the high road and I'll take the low road. Biochem. Pharmacol. 54:1271.
8. Kuschen, G. S., F. Coulin, C. A. Power, A. E. Proudfoot, R. E. Hubbard, A. J. Hoogewerf, and T. N. Wells. 1999. Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry (Mosc.) 38:12959.
9. Witt, D. P., and A. D. Lander. 1994. Differential binding of chemokines to glycosaminoglycan subpopulations. Curr. Biol. 4:394.
10. Hoogewerf, A. J., G. S. Kuschert, A. E. Proudfoot, F. Borlat, I. Clark-Lewis, C. A. Power, and T. N. Wells. 1997. Glycosaminoglycans mediate cell surface oligomerization of chemokines. Biochemistry (Mosc.) 36:13570.
11. Ali, S., A. C. Palmer, B. Banerjee, S. J. Fritchley, and J. A. Kirby. 2000. Examination of the function of RANTES, MIP-1α, and MIP-1β following interaction with heparin-like glycosaminoglycans. J. Biol. Chem. 275:11721.
12. Stringer, S. E., and J. T. Gallagher. 1997. Specific binding of the chemokine platelet factor 4 to heparan sulfate. J. Biol. Chem. 272:20508.
13. Spillmann, D., D. Witt, and U. Lindahl. 1998. Defining the interleukin-8-binding domain of heparan sulfate. J. Biol. Chem. 273:15487.
14. Stringer, S. E., M. J. Forster, B. Mulloy, C. R. Bishop, G. J. Graham, and J. T. Gallagher. 2002. Characterization of the binding site on heparan sulfate for macrophage inflammatory protein 1α. Blood 100:1543.
15. Proudfoot, A. E., S. Fritchley, F. Borlat, J. P. Shaw, F. Vilbois, C. Zwahlen, A. Trkola, D. Marchant, P. R. Clapham, and T. N. Wells. 2001. The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity. J. Biol. Chem. 276:10620.
16. Martin, L., C. Blanpain, P. Garnier, V. Wittamer, M. Parmentier, and C. Vita. 2001. Structural and functional analysis of the RANTES-glycosaminoglycans interactions. Biochemistry (Mosc.) 40:6303.
17. Proudfoot, A. E., T. M. Handel, Z. Johnson, E. K. Lau, P. LiWang, I. Clark-Lewis, F. Borlat, T. N. Wells, and M. H. Kosco-Vilbois. 2003. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc. Natl. Acad. Sci. USA 100:1885.
18. Fernandez, E. J., and E. Lolis. 2002. Structure, function, and inhibition of chemokines. Annu. Rev. Pharmacol. Toxicol. 42:469.
19. Czaplewski, L. G., J. McKeating, C. J. Craven, L. D. Higgins, V. Appay, A. Brown, T. Dudgeon, L. A. Howard, T. Meyers, J. Owen, et al. 1999. Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1α, MIP-1β, and RANTES: characterization of active disaggregated chemokine variants. J. Biol. Chem. 274:16077.
20. Lider, O., E. Baharav, Y. A. Mekori, T. Miller, Y. Naparstek, I. Vlodavsky, and I. R. Cohen. 1989. Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins. J. Clin. Invest. 83:752.
21. Lever, R., and C. P. Page. 2002. Novel drug development opportunities for heparin. Nat. Rev. Drug Discov. 1:140.
22. Douglas, M. S., D. A. Rix, J. H. Dark, D. Talbot, and J. A. Kirby. 1997. Examination of the mechanism by which heparin antagonizes activation of a model endothelium by interferon-γ (IFN-γ). Clin. Exp. Immunol. 107:578.
23. Mack, M., B. Luckow, P. J. Nelson, J. Cihak, G. Simmons, P. R. Clapham, N. Signoret, M. Marsh, M. Stangassinger, F. Borlat, et al. 1998. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J. Exp. Med. 187:1215.
24. Kuziel, W. A., S. J. Morgan, T. C. Dawson, S. Griffin, O. Smithies, K. Ley, and N. Maeda. 1997. Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. Proc. Natl. Acad. Sci. USA 94:12053.
25. Boring, L., J. Gosling, S. W. Chensue, S. L. Kunkel, R. V. Farese, H. E. Broxmeyer, and I. F. Charo. 1997. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J. Clin. Invest. 100:2552.
26. Lu, B., B. J. Rutledge, L. Gu, J. Fiorillo, N. W. Lukacs, S. L. Kunkel, R. North, C. Gerard, and B. J. Rollins. 1998. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J. Exp. Med. 187:601.
27. Gonzalo, J. A., C. M. Lloyd, J. P. Albar, D. Wen, T. N. C. Wells, A. E. I. Proudfoot, C. Martinez-A, T. Bjerke, A. J. Coyle, and J. C. Gutierrez-Ramos. 1998. The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness. J. Exp. Med. 188:157.
28. Campbell, E. M., S. L. Kunkel, R. M. Strieter, and N. W. Lukacs. 1998. Temporal role of chemokines in a murine model of cockroach allergen-induced airway hyperreactivity and eosinophilia. J. Immunol. 161:7047.
29. Karpus, W. J., and R. M. Ransohoff. 1998. Chemokine regulation of experimental autoimmune encephalomyelitis: temporal and spatial expression patterns govern disease pathogenesis. J. Immunol. 161:2667.
30. Butcher, E. C. 1991. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 67:1033.
31. Haribabu, B., R. M. Richardson, I. Fisher, S. Sozzani, S. C. Peiper, R. Horuk, H. Ali, and R. Snyderman. 1997. Regulation of human chemokine receptors CXCR4. Role of phosphorylation in desensitization and internalization. J. Biol. Chem. 272:28726.
32. Aragay, A. M., M. Mellado, J. M. Frade, A. M. Martin, M. C. Jimenez-Sainz, A. Martinez, and F. Mayor, Jr. 1998. Monocyte chemoattractant protein-1-induced CCR2B receptor desensitization mediated by the G protein-coupled receptor kinase 2. Proc. Natl. Acad. Sci. USA 95:2985.
33. Richardson, R. M., B. C. Pridgen, B. Haribabu, and R. Snyderman. 2000. Regulation of the human chemokine receptor CCR1: cross-regulation by CXCR1 and CXCR2. J. Biol. Chem. 275:9201.
34. Frevert, C. W., M. G. Kinsella, C. Vathanaprida, R. B. Goodman, D. G. Baskin, A. Proudfoot, T. N. Wells, T. N. Wight, and T. R. Martin. 2003. Binding of interleukin-8 to heparan sulfate and chondroitin sulfate in lung tissue. Am. J. Respir. Cell Mol. Biol. 28:464.
35. Steed, P. M., M. G. Tansey, J. Zalevsky, E. A. Zhukovsky, J. R. Desjarlais, D. E. Szymkowski, C. Abbott, D. Carmichael, C. Chan, L. Cherry, et al. 2003. Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science 301:1895.
36. Ransohoff, R. M. 2002 The chemokine system in neuroinflammation: an update. J Infect. Dis. 186(Suppl. 2):S152.
37. Sorensen, T. L., M. Tani, J. Jensen, V. Pierce, C. Lucchinetti, V. A. Q. Folcik, J. Rottman, F. Sellebjerg, R. M. Strieter, and J. L. R. Frederiksen. 1999. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. Invest. 103:807.
38. Hajeer, A. H., F. al Sharif, and W. E. Ollier. 1999. A polymorphism at position -403 in the human RANTES promoter. Eur. J. Immunogenet. 26:375.
39. al Sharif, F., W. E. Ollier, and A. H. Hajeer. 1999. A rare polymorphism at position -28 in the human RANTES promoter. Eur. J. Immunogenet. 26:373.
40. Karpus, W. J., and K. J. Kennedy. 1997. MIP-1α and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J. Leukocyte Biol. 62:681.
41. Izikson, L., R. S. Klein, I. F. Charo, H. L. Weiner, and A. D. Luster. 2000. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J. Exp. Med. 192:1075.
42. Huang, D., J. Wang, P. Kivisakk, B. J. Rollins, and R. M. Ransohoff. 2001. Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J. Exp. Med. 193:713.
43. Liang, M., C. Mallari, M. Rosser, H. P. Ng, K. May, S. Monahan, J. G. Bauman, I. Islam, A. Ghannam, B. Buckman, et al. 2000. Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J. Biol Chem. 275:19000.
44. Kennedy, K. J., R. M. Stricter, S. L. Kunkel, N. W. Lukacs, and W. J. Karpus. 1998. Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1α and monocyte chemotactic protein-1. J. Neuroimmunol. 92:98.
45. Matsui, M., J. Weaver, A. E. Proudfoot, J. R. Wujek, T. Wei, E. Richer, B. D. Trapp, A. Rao, and R. M. Ransohoff. 2002. Treatment of experimental autoimmune encephalomyelitis with the chemokine receptor antagonist Met-RANTES. J. Neuroimmunol. 128:16.
46. Glabinski, A. R., B. Bielecki, and R. M. Ransohoff. 2003. Chemokine upregulation follows cytokine expression in chronic relapsing experimental autoimmune encephalomyelitis. Scand. J. Immunol. 58:81.
47. Bagaeva, L. V., L. P. Williams, and B. M. Segal. 2003. IL-12 dependent/IFN-γ independent expression of CCR5 by myelin-reactive T cells correlates with encephalitogenicity. J. Neuroimmunol. 137:109.
48. Glass, W. G., M. J. Hickey, J. L. Hardison, M. T. Liu, J. E. Manning, and T. E. Lane. 2004. Antibody targeting of the CC chemokine ligand 5 results in diminished leukocyte infiltration into the central nervous system and reduced neurologic disease in a viral model of multiple sclerosis. J. Immunol. 172:4018.